Skip to content
Review Open access

Nanomedicine for Alzheimer's Disease: A Stage-Matched Framework Integrating Pathological Network Modulation, Blood-Brain Barrier Delivery, and Clinical Translation.

Oct 2026 · Pharmacological Research · pp. 109709 · 0 citations · 279 references
Medicine

Abstract

Alzheimer's disease (AD) remains one of the most difficult neurodegenerative disorders to treat. Therapeutic failure is driven mainly by two barriers: the multifactorial pathological network of AD and the limited access of most therapeutics to the brain imposed by the blood-brain barrier (BBB). Conventional symptomatic drugs and emerging antibody-based therapies provide clinical benefit, but they do not fully address the interacting processes involving amyloid-β (Aβ) accumulation, Tau pathology, neuroinflammation, mitochondrial dysfunction, oxidative stress, and synaptic impairment. In this review, we discuss nanomedicine as an integrated platform for AD intervention. We summarize the major pathological nodes that provide targets for nanomedicine-based therapy and discuss BBB structure and transport mechanisms. We then compare polymeric, inorganic, carbon-based, lipid-based, protein-based, nucleic acid-based, and biomimetic platforms in terms of delivery function, intrinsic bioactivity, pathological modulation, and translational risk. Assisted brain-delivery strategies are also discussed, including focused ultrasound-mediated BBB modulation and intranasal nose-to-brain delivery. We then review clinical-stage AD nanomedicine candidates and summarize the key barriers to their translation. This review integrates stage-dependent pathology, BBB transport, and nanoplatform properties. It proposes a stage-matched framework for preclinical, mild symptomatic, and moderate-severe AD. At each stage, the framework matches active pathological nodes with feasible BBB transport strategies, carrier features, and administration routes. It may guide the development of mechanistically defined, reproducible, and clinically testable nanomedicines.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.